Lates News

According to a quick news flash from Every Economy AI, on April 17th China Post Securities released a research report giving a "buy" rating to Taige Pharmaceutical (300347.SZ). The main reasons for this rating include: 1) The volume and price of new signed orders are stable, with sufficient orders in hand to guarantee future growth; 2) Deepening global operational capabilities, with overseas operations becoming the core growth engine. (Everyday Economic News)